Contact
Please use this form to send email to PR contact of this press release:
NEMUS Bioscience and Catalent to Advance NB1222 into Human Dosage Formulation Development
TO:
Please use this form to send email to PR contact of this press release:
NEMUS Bioscience and Catalent to Advance NB1222 into Human Dosage Formulation Development
TO: